165 related articles for article (PubMed ID: 11107449)
1. Should women receiving tamoxifen be screened for endometrial cancer? An argument for screening.
Menzin AW; Gal D; Barakat RR
Cancer Invest; 2000; 18(8):793-7. PubMed ID: 11107449
[No Abstract] [Full Text] [Related]
2. Gynecologic surveillance of women on tamoxifen: first do no harm.
Runowicz CD
J Clin Oncol; 2000 Oct; 18(20):3457-8. PubMed ID: 11032584
[No Abstract] [Full Text] [Related]
3. Should tamoxifen users be screened for endometrial lesions?
Neven P; Vergote I
Lancet; 1998 Jan; 351(9097):155-7. PubMed ID: 9449866
[No Abstract] [Full Text] [Related]
4. Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer.
Barakat RR
J Clin Oncol; 1999 Jul; 17(7):1967-8. PubMed ID: 10561245
[No Abstract] [Full Text] [Related]
5. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
Jordan VC; Morrow M
J Natl Cancer Inst; 2003 May; 95(9):683-4; author reply 684-5. PubMed ID: 12734320
[No Abstract] [Full Text] [Related]
6. Tamoxifen therapy for breast cancer and endometrial cancer risk.
Bernstein L; Deapen D; Cerhan JR; Schwartz SM; Liff J; McGann-Maloney E; Perlman JA; Ford L
J Natl Cancer Inst; 1999 Oct; 91(19):1654-62. PubMed ID: 10511593
[TBL] [Abstract][Full Text] [Related]
7. [The interruption of a study following an "ad interim" analysis. The example of the NSABP-P1 study].
Savarese A
Suppl Tumori; 2004; 3(4):S23-4. PubMed ID: 15206204
[No Abstract] [Full Text] [Related]
8. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen side effects may be attributable to other causes.
Jones J
J Natl Cancer Inst; 2001 Jan; 93(1):11-2. PubMed ID: 11136833
[No Abstract] [Full Text] [Related]
10. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.
Barakat RR; Gilewski TA; Almadrones L; Saigo PE; Venkatraman E; Hudis C; Hoskins WJ
J Clin Oncol; 2000 Oct; 18(20):3459-63. PubMed ID: 11032585
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen: a new risk factor for cerebral sinus thrombosis.
Masjuan J; Pardo J; Callejo JM; Andrés MT; Alvarez-Cermeño JC
Neurology; 2004 Jan; 62(2):334-5. PubMed ID: 14745086
[No Abstract] [Full Text] [Related]
12. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen: an enduring star.
Veronesi U; Maisonneuve P; Decensi A
J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
[No Abstract] [Full Text] [Related]
14. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract][Full Text] [Related]
15. Screening recommendation for women taking tamoxifen.
Kawabata H; Ueno T
Lancet; 2001 Sep; 358(9286):1018. PubMed ID: 11593503
[No Abstract] [Full Text] [Related]
16. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
[TBL] [Abstract][Full Text] [Related]
17. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen and risk of endometrial cancer.
Marsh F; Mayfield M
Lancet; 2001 Jan; 357(9249):68. PubMed ID: 11197382
[No Abstract] [Full Text] [Related]
19. Tamoxifen and risk of endometrial cancer.
Kairies P
Lancet; 2001 Jan; 357(9249):68. PubMed ID: 11197381
[No Abstract] [Full Text] [Related]
20. Tamoxifen and risk of endometrial cancer.
Dickson MJ; Pandiarajan T
Lancet; 2001 Jan; 357(9249):67-8. PubMed ID: 11197380
[No Abstract] [Full Text] [Related]
[Next] [New Search]
